Glycosmedia Weekly Diabetes News - 03/31/2023

THIS IS THE FINAL EDITION OF GLYCOSMEDIA

Anyone interested in purchasing Glycosmedia should contact the Editor-in-Chief Jim Young to discuss. jim@glycosmedia.com

Effects of Semaglutide on Albuminuria and Kidney Function in People With Overweight or Obesity With or Without Type 2 Diabetes: Exploratory Analysis From the STEP 1, 2, and 3 Trials

Semaglutide improved UACR in adults with overweight/obesity and type 2 diabetes. In participants with normal kidney function, semaglutide did not have an effect on eGFR decline (Diabetes Care)

Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes A Randomized Clinical Trial

Verapamil partially preserved stimulated C-peptide secretion at 52 weeks compared with placebo and was well tolerated in children and adolescents with newly diagnosed type 1 diabetes (JAMA)

Effect of Tight Glycemic Control on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes – A Randomized Clinical Trial

Intensive diabetes management with automated insulin delivery did not affect the decline in pancreatic C-peptide secretion at 52 weeks in youths with newly diagnosed type 1 diabetes (JAMA)

Glycaemic control in people with diabetes following acute myocardial infarction

The evidence supporting the use of continuous glucose monitoring technology in type 2 diabetes is growing and it may provide a novel intervention for improving glycaemic control post infarct (Diabetes Research and Clinical Practice)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study

In this real-world type 2 diabetes population, discontinuation of GLP-1 RA treatment was associated to a higher risk of major cardiovascular events, in both subjects with and without a history of CV events (Cardiovascular Diabetology )

SGLT-2 inhibitors in type 2 diabetes

We hope that this document will pragmatically support those involved in the day-to-day care of people with type 2 diabetes in the “here and now”, with the aim of maximising the benefits and minimising harm (ABCD)

Gastrointestinal Consequences of Type 2 Diabetes Mellitus and Impaired Glycemic Homeostasis: A Mendelian Randomization Study

Associations were found between genetic liability to type 2 diabetes and an increased risk of a broad range of GDs, highlighting the importance of GD prevention in patients with type 2 diabetes (Diabetes Care)

Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER PLUS phase 3 trial

The PIONEER clinical development programme for oral semaglutide currently comprises nine phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 10,000 adults with type 2 diabetes in total. Oral semaglutide 3 mg, 7 mg and 14 mg are approved under the brand name Rybelsus®, indicated for type 2 diabetes (Novo Nordisk)